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Introduction: Since 1991, three sequential prospective
multi-national clinical trials (including 39 participating in-
stitutions) have been conducted by the “Head Start” Con-
sortium for young children newly-diagnosed with malignant
brain tumors, designed to improve both the cure rate and
quality of survival of such children through replace-
ment (<6yo) or reduction in dosage of brain irradiation (6-
10yo) by a single cycle of marrow-ablative chemotherapy
with autologous hematopoieic cell rescue as consolidation
following initial induction chemotherapy. We present data
documenting progressively decreasing morbidity and mor-
tality of the marrow-ablative consolidation phase of treat-
ment as well as the improvement in disease-speciﬁc survival.
Methods: Overall treatment design has remained un-
changed throughout the 3 prospective trials; 5 cycles of in-
duction chemotherapy (vincristine, cisplatin, etoposide,
cyclophosphamide with/without high-dose methotrexate
(HD-MTX) over 4 days each 21-28 days cycle (HSI-II) or 3
cycles of the prior regimen + HD-MTX alternating with 2
cycles of vincristine, oral etoposide, temozolomide and
cyclophosphamide) were followed efor patients with mini-
mal residual, non-progressive tumor - by a single marrow-
ablative cycle consisting of thiotepa (300mg/M2/day x 3
days), etoposide (250mg/M2/day x 3 days) on days -5 to -3,
preceded by carboplatin (500mg/M2/day or AUC of 6/day by
Calvert formula, whichever was the lower of the methods of
dosing) on days -8 to -6. Bone Marrow (HSI) or leukapher-
esed peripheral blood hematopoietic cells under Neupogen
stimulation (HSII-III) were obtained following recovery
from the ﬁrst and/or second induction cycles. Radiotherapy
was reserved for patients with residual tumor following
completion of induction or >6yo.
Results: A total of 216 children were enrolled on 3 consec-
utive HS trials with medulloblastoma, other primitive neuro-
ectodermal tumors, ependymoma, atypical teratoid/rhab-
doid tumors, malignant glial tumors and other malignant
CNS tumors and underwent marrow-ablative chemotherapy,
the 100 day toxic mortality for whom steadily declined from
HSI (3/37¼8.1%; 1 day +4 hepato-renal failure; 1 day +26 viral
pneumonitis post-multi-organ system failure; 1 day +21
post-respiratory arrest due to oropharyngeal mucositis)
through HSII (1/46¼2.2%; pseudomonas aerugenosa sepsis)
to HSIII (1/131 ¼ 0.8%; VOD day +21). Data on time to
engraftment, transplant-related morbidities and long-term
disease-speciﬁc survival will also be presented.
Conclusions: Increasing experience with the marrow-abla-
tive chemotherapy regimen, combined with improved leu-
kapheresis and post-reinfusion supportive care techniques,
have likely contributed to the steady decline in transplant-
related mortality in this patient population and contributed
towards improved overall survival.88
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Background: TBI-based preparative regimen has been
widely recommended for pediatric ALL. These assumptions
are based on older registry studies. Because of the signiﬁ-
cantly high rates of serious late effect using TBI in pediatric
patients it is of utmost importance to ﬁnd alternative regi-
mens. Chemotherapy regimens are developed to minimize
the toxicities of irradiation-based regimens.
Methods: Since the year 1994, 111 pediatric patients (78
male &33 female: 72 in CR and 39 not in CR) with ALL un-
derwent HSCT in our center using a TBI-free conditioning.
Here, we describe the outcomes of HSCT of the 72 patients in
CR: 30 patients were in ﬁrst CR, 28 second CR, and 14 third
CR. Only very high-risk patients underwent HSCT in the ﬁrst
CR. Patients were treated and classiﬁed according to BFM
protocols. The conditioning regimen was included of
Busulfan (IV or Oral) and Cyclophosphamide with or without
ATG. For GVHD prophylaxis, patients received cyclosporine
with or without methotrexate.
Outcomes: Patients underwent transplantation from sib-
ling donors (n¼58), other related donors (n¼10), unre-
lated donor (n¼4). Source of grafts were peripheral blood
(n¼60), bone marrow (n¼7) and cord blood (n¼5). The
probability of neutrophil engraftment (at day60) was 94+-
3% (med.time to of 14days) and of platelets-engraftment
was 90+-10% (med.time 22days). The estimated 5-year
leukemic free survival (LFS) was 73%+-6% (82+-7% in CR1,
71+-10% in CR2 and 38+-25% in CR>¼2). Relapse rates
were 8+-5% in CR1, 22+-9% in CR2 and 20+-17% in CR>¼2.
Acute GvHD grade 2-4 occurred in 49+-5% patients and
15+-5% patients have experienced chronic extended
GvHD.
Conclusion: A TBI-free (Bu/Cy) preparative regimens can be
used in pediatric ALL with encouraging LFS rates, similar to
what is reported in literature using TBI. Well-designed ran-
domized trials are needed to better clarify the difference
between radiation and TBI-free conditioning regimens in
pediatric ALL, including late effects.
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In 2009, we initiated a prospective study of chimerism-
based preemptive IT consisting of fast withdrawal of
Table 1: Relapse rates in patients with MC and FD chimerism in whole BM,
PB, and subsets
Chimerism N* Mixed chimerism
(MC)
Full donor
chimerism (FDC)
EFS
N with
MC
Relapse
rate in
pts with
MC
N with
FDC
Relapse
rate in
pts with
FDC
Log
Rank
P value
Whole BM 39 26 35% 13 15% 0.1
BM - CD3 subset 29 24 25% 5 0% 0.09
BM - Leukemia
speciﬁc subset
33 17 35% 16 6% 0.002
BM- CD34 subset 31 21 33% 10 10% 0.04
All BM subsets 37 30 33% 7 0% 0.03
Whole PB 42 22 32% 20 25% 0.8
PB -CD3 subset 42 31 32% 11 18% 0.6
PB - Leukemia
speciﬁc subset
42 19 26% 23 30% 0.8
All PB subsets 43 35 34% 8 12% 0.14
* Number of patients who had early post-HCT chimerism test done on a
speciﬁc subset.
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fusions (DLI) in children receiving HCT for leukemia. We
enrolled 43 patients. Donors and stem cell sources
included matched related (49%), matched unrelated (30%)
and mismatched unrelated donors (21%) of BM (53%) and
peripheral blood (PB) (47%). Chimerism analyses on whole
PB and BM and subsets were done using a semi-quanti-
tative PCR-based method (1% sensitivity), on day
32.5SD8 (PB) and day3810 (BM). If mixed chimerism
(MC) was found in any PB or BM subset on 2 tests, FWI
over 2-4 weeks was initiated, followed by DLI if MC per-
sisted. The end point for IT was full donor (FD) chimerism
in all PB subsets or development of GVHD. Patients with
GVHD or FD chimerism in all subsets were assigned to the
observation group (N¼12); patients with MC in any subset
were assigned to the IT group (N¼26). 15 patients received
FWI and DLI and 11 received FWI only. Five patients could
not be assigned to either group due to early toxic death
(N¼1) or relapse (N¼4). Follow-up of living patients is
28.89.7 months. Events included relapse (N¼13) and
toxic death (N¼2), one of which was intervention related,
resulting in 4% treatment-related mortality. Estimated 36-
mos EFS is 8310% for the observation group, 5414% for
the IT group and 5610% for the entire cohort, including
unassigned patients. Acute and/or chronic GVHD devel-
oped in 5/26 (19%) patients following IT. Residual disease
(RD) prior to HCT remained a predictor of EFS. Despite IT
7/11 patients with RD and 6/26 without, developed
relapse (Log Rank p<0.001). Early post-HCT BM chime-
rism was better predictor of EFS than PB chimerism (Table
1). We recommend that post-HCT IT continues until 100%
chimerism in all BM subsets is achieved.90
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Angeles, CABackground: Genetic lymphohematopoietic diseases have
been effectively cured by performing allogeneic blood and
marrow transplant (BMT) from a histocompatible sibling,
following a standard conditioning regimen with busulfan
(BU), cyclophosphamide (CY), and antithymocyte globulin
(ATG). However, the high levels of transplant related mor-
tality (TRM) and morbidity with this regimen limits its more
widespread use as curative therapy.
Objective: To determine the safety, donor chimerism and
complications associated with de-escalation of CY, in a
reduced toxicity conditioning regimen with ﬂudarabine and
alemtuzumab, prior to HLA-matched sibling donor trans-
plantation among pediatric recipients with genetic lym-
phohematopoietic diseases.
Methods: Eligible patients were consented at Children’s
Hospital Los Angeles, Stanford Hospital and Lucile Packard
Children’s Hospital between 2008 and 2013. The condition-
ing regimen consisted of Busulfan 16 mg/kg, Cyclophospha-
mide 105mg/m2 Fludarabine 105mg/m2, and Alemtuzumab
52mg/m2. Graft versus host disease prophylaxis consisted of
steroids and a calcineurin inhibitor.
Results: The study population was 68% female with a me-
dian age of 5.25 ( 5.9 years). Patients pre-transplant di-
agnoses included Sickle Cell Disease (n¼7), Thalassemia
(n¼4); Kostmann’s Syndrome (n¼2), Chronic Granuloma-
tous Disease (n¼1), Chediak Higashi syndrome (n¼1),
hemophagocytic lymphohistiocytosis (n¼2), Cartilage Hair
Hypoplasia (n¼1), Diamond Blackfan Anemia (n¼2), and
Hurler’s syndrome (n¼2). The median total nucleated cell
count (TNC) and CD34 dose was 4.6x108 ( 2.26x108) cells/
kg and 8.5x106 ( 5.2x106) cells/kg respectively. All pa-
tients had an initial donor chimerism >90% (median 99%).
The median time to neutrophil engraftment (>500 cells/
mL) and platelet engraftment (>20K cells/microliter) were
19 (9.7) and 23.5 ( 26.2) days respectively. One patient
required a stem cell boost on day +83 (poor count recovery
due to CMV). There were no cases of veno-occlussive dis-
ease or Grade III/IV acute or extensive chronic GVHD. In-
fectious complications (Figure 2) included CMV viremia
(n¼5), EBV viremia (n¼1), mucoromycosis (n¼1) and
adenoviremia (n¼1); two patients expired, one from
pneumonitis (EBV viremia) and the other from mucormy-
cosis. Overall survival (OS) at 100 days was 95%; with a
median follow up of 1 ( 2.05) years, the OS is 90%, with all
patients sustaining high-level donor chimerism and a
median Lansky/Karnofsky score of 100. Conclusion: A
reduced toxicity conditioning regimen with reduced doses
of CY achieves durable engraftment of stem cells from
related donors among patients with genetic lymphohe-
matopoietic diseases and low rates of transplant related
mortality and morbidity. Longer follow-up is required to
assess for a potential reduction in late effects associated
with this regimen.
